Ameriprise
AZN icon

Ameriprise’s AstraZeneca AZN Stock Holding History

Ameriprise’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13B Buy
5,747,087
+499,287
+10% +$96.3M 0.26% 84
2025
Q4 		$966M Buy
5,247,800
+2,394,019
+84% +$420M 0.22% 96
2025
Q3 		$438M Buy
2,853,781
+330,285
+13% +$50M 0.1% 211
2025
Q2 		$352M Buy
2,523,496
+52,312
+2% +$7.33M 0.09% 237
2025
Q1 		$364M Buy
2,471,184
+130,532
+6% +$18.9M 0.1% 217
2024
Q4 		$306M Buy
2,340,652
+195,204
+9% +$27.3M 0.08% 252
2024
Q3 		$334M Sell
2,145,448
-297,604
-12% -$48M 0.09% 241
2024
Q2 		$382M Buy
2,443,052
+17,656
+0.7% +$2.66M 0.1% 207
2024
Q1 		$328M Buy
2,425,396
+203,094
+9% +$26.9M 0.09% 233
2023
Q4 		$299M Buy
2,222,302
+100,948
+5% +$13.1M 0.09% 235
2023
Q3 		$287M Buy
2,121,354
+100,552
+5% +$13.7M 0.09% 217
2023
Q2 		$289M Buy
2,020,802
+415,735
+26% +$61.2M 0.09% 230
2023
Q1 		$223M Sell
1,605,067
-12,367
-0.8% -$1.66M 0.07% 278
2022
Q4 		$219M Sell
1,617,434
-141,111
-8% -$17.7M 0.08% 270
2022
Q3 		$193M Sell
1,758,545
-84,209
-5% -$10.7M 0.07% 285
2022
Q2 		$243M Sell
1,842,754
-137,833
-7% -$18.1M 0.08% 250
2022
Q1 		$263M Buy
1,980,587
+107,469
+6% +$12.9M 0.08% 267
2021
Q4 		$218M Buy
1,873,118
+505,736
+37% +$59.5M 0.06% 331
2021
Q3 		$164M Buy
1,367,382
+1,254,493
+1,111% +$146M 0.05% 378
2021
Q2 		$13.5M Sell
112,889
-57,656
-34% -$6.33M ﹤0.01% 1670
2021
Q1 		$17M Sell
170,545
-10,443
-6% -$1.05M 0.01% 1455
2020
Q4 		$18.1M Buy
180,988
+41,647
+30% +$4.41M 0.01% 1296
2020
Q3 		$15.3M Sell
139,341
-34,531
-20% -$3.84M 0.01% 1250
2020
Q2 		$18.4M Sell
173,872
-11,245
-6% -$1.16M 0.01% 1103
2020
Q1 		$16.5M Buy
185,117
+2,190
+1% +$206K 0.01% 1056
2019
Q4 		$18.2M Buy
182,927
+18,403
+11% +$1.73M 0.01% 1263
2019
Q3 		$14.7M Sell
164,524
-689
-0.4% -$59.7K 0.01% 1384
2019
Q2 		$13.6M Sell
165,213
-55,071
-25% -$4.32M 0.01% 1478
2019
Q1 		$17.8M Sell
220,284
-116,859
-35% -$9.21M 0.01% 1228
2018
Q4 		$25.6M Buy
337,143
+11,706
+4% +$914K 0.01% 920
2018
Q3 		$25.8M Sell
325,437
-867,912
-73% -$65.6M 0.01% 1111
2018
Q2 		$83.9M Sell
1,193,349
-303,564
-20% -$21.8M 0.04% 460
2018
Q1 		$105M Sell
1,496,913
-84,114
-5% -$5.83M 0.05% 369
2017
Q4 		$110M Buy
1,581,027
+67,636
+4% +$4.56M 0.05% 353
2017
Q3 		$103M Buy
1,513,391
+99,760
+7% +$6.3M 0.05% 361
2017
Q2 		$96.8M Buy
1,413,631
+78,646
+6% +$5.14M 0.05% 360
2017
Q1 		$83.9M Buy
1,334,985
+256,764
+24% +$14.9M 0.04% 390
2016
Q4 		$58.5M Buy
1,078,221
+190,622
+21% +$10.8M 0.03% 481
2016
Q3 		$58.4M Buy
887,599
+254,618
+40% +$16.6M 0.03% 453
2016
Q2 		$38.2M Buy
632,981
+169,257
+36% +$9.83M 0.02% 591
2016
Q1 		$25.5M Buy
463,724
+104,650
+29% +$6.29M 0.02% 786
2015
Q4 		$24.4M Buy
359,074
+4,761
+1% +$312K 0.01% 822
2015
Q3 		$22.7M Sell
354,313
-213,939
-38% -$14.1M 0.01% 854
2015
Q2 		$36.2M Buy
568,252
+372,148
+190% +$25.5M 0.02% 658
2015
Q1 		$13.4M Sell
196,104
-738,512
-79% -$51.3M 0.01% 1315
2014
Q4 		$65.8M Buy
934,616
+741,920
+385% +$53.1M 0.04% 434
2014
Q3 		$13.8M Buy
192,696
+19,382
+11% +$1.42M 0.01% 1207
2014
Q2 		$12.9M Sell
173,314
-675,500
-80% -$48.8M 0.01% 1337
2014
Q1 		$55.1M Sell
848,814
-136,016
-14% -$8.78M 0.03% 506
2013
Q4 		$58.5M Buy
984,830
+43,403
+5% +$2.36M 0.04% 478
2013
Q3 		$48.9M Sell
941,427
-972,093
-51% -$48.8M 0.03% 529
2013
Q2 		$90.5M Buy
+1,913,520
New +$97.4M 0.06% 345

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Ameriprise's AZN Position: Q1 2026 in Review

Ameriprise increased its AstraZeneca (AZN) stake by 9.5% in Q1 2026, buying an estimated $96.3M and bringing the position to 5,747,087 shares worth $1.13B. The position accounts for 0.26% of the portfolio, ranked #84.

Ameriprise first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Ameriprise held 5,747,087 shares of AstraZeneca worth $1.13B as of Q1 2026.
  • Ameriprise bought 499,287 AstraZeneca shares in Q1 2026, an estimated $96.3M.
  • AstraZeneca made up 0.26% of Ameriprise's portfolio in Q1 2026, its #84 holding.
  • Ameriprise first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.